{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T23:19:09Z","timestamp":1761175149510,"version":"build-2065373602"},"reference-count":12,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,2,11]],"date-time":"2021-02-11T00:00:00Z","timestamp":1613001600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000761","name":"Imperial College London","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000761","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ijidonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Infectious Diseases"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.ijid.2021.02.056","type":"journal-article","created":{"date-parts":[[2021,2,17]],"date-time":"2021-02-17T11:33:26Z","timestamp":1613561606000},"page":"274-276","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["The role of ibrutinib in COVID-19 hyperinflammation: A case report"],"prefix":"10.1016","volume":"105","author":[{"given":"Suzanne","family":"Maynard","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose","family":"Ros-Soto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aris","family":"Chaidos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Innes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krushika","family":"Paleja","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eitan","family":"Mirvis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noora","family":"Buti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harriet","family":"Sharp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renuka","family":"Palanicawandar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dragana","family":"Milojkovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijid.2021.02.056_bib0005","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1200\/JCO.2012.42.7906","article-title":"Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed\/refractory B-cell malignancies","volume":"31","author":"Advani","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijid.2021.02.056_bib0010","doi-asserted-by":"crossref","first-page":"e307","DOI":"10.3324\/haematol.2017.186908","article-title":"Ibrutinib withdrawal symptoms in patients with Waldenstrom macroglobulinemia","volume":"103","author":"Castillo","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.ijid.2021.02.056_bib0015","article-title":"Covid-19: remdesivir has little or no impact on survival, WHO trial shows","volume":"371","author":"Dyer","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.ijid.2021.02.056_bib0020","doi-asserted-by":"crossref","first-page":"L52","DOI":"10.1152\/ajplung.00047.2018","article-title":"Inhibiting Bruton\u2019s tyrosine kinase rescues mice from lethal influenza-induced acute lung injury","volume":"315","author":"Florence","year":"2019","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"10.1016\/j.ijid.2021.02.056_bib0025","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofv098","article-title":"Acute phase reactants in infections: evidence-based review and a guide for clinicians","volume":"2","author":"Markanday","year":"2015","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.ijid.2021.02.056_bib0030","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1182\/blood.2020006965","article-title":"Outcomes of COVID-19 in patients with CLL: a multicenter international experience","volume":"136","author":"Mato","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.ijid.2021.02.056_bib0035","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0140-6736(20)30628-0","article-title":"COVID-19: consider cytokine storm syndromes and immunosuppression","volume":"395","author":"Mehta","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ijid.2021.02.056_bib0040","article-title":"Remdesivir for severe covid-19: a clinical practice guideline","volume":"371","author":"Rochwerg","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.ijid.2021.02.056_bib0045","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1111\/bjh.16863","article-title":"Protective role of Bruton tyrosine kinase inhibitors in patients with chronic lymphocytic leukaemia and COVID-19","volume":"190","author":"Thibaud","year":"2020","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ijid.2021.02.056_bib0050","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1182\/blood.2020006288","article-title":"The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19-infected patients","volume":"135","author":"Treon","year":"2020","journal-title":"Blood"},{"year":"2020","series-title":"Ibrutinib for the treatment of COVID-19 in patients requiring hospitalization","author":"Woyach","key":"10.1016\/j.ijid.2021.02.056_bib0055"},{"key":"10.1016\/j.ijid.2021.02.056_bib0060","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.jinf.2020.03.037","article-title":"The pathogenesis and treatment of the `Cytokine Storm\u2019 in COVID-19","volume":"80","author":"Ye","year":"2020","journal-title":"J Infect"}],"container-title":["International Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971221001429?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971221001429?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T07:58:45Z","timestamp":1761119925000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1201971221001429"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":12,"alternative-id":["S1201971221001429"],"URL":"https:\/\/doi.org\/10.1016\/j.ijid.2021.02.056","relation":{},"ISSN":["1201-9712"],"issn-type":[{"type":"print","value":"1201-9712"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role of ibrutinib in COVID-19 hyperinflammation: A case report","name":"articletitle","label":"Article Title"},{"value":"International Journal of Infectious Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijid.2021.02.056","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2021 Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.","name":"copyright","label":"Copyright"}]}}